Atrioventricular nodal reentrant tachycardia (AVNRT) is a type of arrhythmia that affects the heart’s electrical system and causes an abnormally rapid heartbeat. It is one of the most common forms of tachycardia, or rapid heart rate, and is usually seen in younger people. AVNRT is usually benign and does not cause any long-term damage to the heart. However, it can cause symptoms such as dizziness, lightheadedness, palpitations, chest pain, and shortness of breath, which can be quite uncomfortable. The electrical system of the heart is composed of four chambers, the atria and the ventricles. Electrical signals travel through the atria and then the ventricles, causing them to contract in a coordinated manner. In AVNRT, a reentrant circuit is created within the atrioventricular node (AV node), which is a small area of specialized tissue located between the atria and the ventricles. This circuit causes the electrical signals to be delayed, resulting in a rapid heartbeat.
The AV node is a small area of specialized tissue located between the atria and the ventricles. It is composed of two main components: the sinus node and the atrioventricular node. The sinus node is responsible for generating the electrical signals that cause the heart to beat. The AV node is responsible for conducting the electrical signals from the atria to the ventricles. The AV node is composed of several different types of cells, including Purkinje cells, myocytes, and fibroblasts. The Purkinje cells are responsible for conducting the electrical signals from the sinus node to the atria and the ventricles. The myocytes are responsible for conducting the electrical signals from the atria to the ventricles. Finally, the fibroblasts are responsible for providing structural support to the AV node.
AVNRT is caused by a reentrant circuit within the AV node. This circuit is created when the electrical signals travel from the sinus node to the atria, and then back to the sinus node. This creates a loop, which causes the electrical signals to be delayed, resulting in a rapid heartbeat. The reentrant circuit is created when the electrical signals travel down two different pathways within the AV node. The first pathway is the slow pathway, which is composed of Purkinje cells. The second pathway is the fast pathway, which is composed of myocytes. The slow pathway conducts the electrical signals from the sinus node to the atria, and then back to the sinus node. The fast pathway conducts the electrical signals from the atria to the ventricles, and then back to the atria. When the electrical signals travel down both pathways, they create a loop, which causes the electrical signals to be delayed, resulting in a rapid heartbeat.
AVNRT is usually diagnosed through an electrocardiogram (ECG) or an echocardiogram. An ECG is used to measure the electrical activity of the heart, and can help to identify if there is a reentrant circuit within the AV node. An echocardiogram is used to measure the structure and function of the heart, and can help to identify any underlying causes of the arrhythmia. AVNRT can usually be treated with medication or with a procedure known as radiofrequency ablation. Medications, such as beta-blockers or calcium channel blockers, are used to slow down the electrical signals in the heart. Radiofrequency ablation is a procedure in which a catheter is inserted into the heart, and high-frequency energy is used to destroy the abnormal electrical pathways in the AV node.
Atrioventricular nodal reentrant tachycardia (AVNRT) is a type of arrhythmia that affects the heart’s electrical system and causes an abnormally rapid heartbeat. It is usually benign and does not cause any long-term damage to the heart, but it can cause uncomfortable symptoms such as dizziness, lightheadedness, palpitations, chest pain, and shortness of breath. AVNRT is usually diagnosed through an electrocardiogram or an echocardiogram, and can be treated with medication or with a procedure known as radiofrequency ablation. Understanding the anatomy and mechanisms of AVNRT is essential in diagnosing and treating this condition.
1.
According to the CAPTIVATE Study, fixed-duration ibrutinib plus venetoclax may be beneficial for patients with high-risk chronic lymphocytic leukemia.
2.
Scientists develop novel adjuvant delivery system to enhance cancer vaccine effectiveness
3.
Vepdegestrant Earns FDA Nod for ESR1-Mutated Breast Cancer
4.
According to a study, taking part in a clinical trial for cancer may not actually increase survival.
5.
A new blood test greatly increases the ability to detect cancer.
1.
Cancer Memory: A Persistent Threat to Tumor Recurrence and Metastasis
2.
Unraveling the Mysteries of Hematocrit: How It Impacts Your Health
3.
The Transformative Power of Genomics in the Diagnosis and Management of Rare Cancers
4.
Omega-3 Fatty Acids as Molecular Adjuvants Against Chemoresistance in Breast Cancer
5.
Surprising Symptoms of Prostate Cancer: What You Need to Know
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Navigating the Complexities of Ph Negative ALL - Part X
2.
Efficient Management of First line ALK-rearranged NSCLC - Part III
3.
What Therapy Would Yield the Best Outcomes In Patients with R/R B-cell ALL?
4.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part IV
5.
Updates on Standard V/S High Risk Myeloma Treatment- The Next Part
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation